These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38003581)

  • 1. In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction.
    García-Aguilar A; Campi-Caballero R; Visoso-Carvajal G; García-Sánchez JR; Correa-Basurto J; García-Machorro J; Espinosa-Raya J
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003581
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.
    Sevenich M; van den Heuvel J; Gering I; Mohrlüder J; Willbold D
    J Virol; 2022 Jul; 96(13):e0068522. PubMed ID: 35674432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19.
    Dakal TC
    Immunobiology; 2021 Jan; 226(1):152021. PubMed ID: 33232865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
    Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
    Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model.
    Uematsu T; Takano T; Matsui H; Kobayashi N; Ōmura S; Hanaki H
    J Antibiot (Tokyo); 2023 Aug; 76(8):481-488. PubMed ID: 37185581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.
    Ragotte RJ; Pulido D; Donnellan FR; Hill ML; Gorini G; Davies H; Brun J; McHugh K; King LDW; Skinner K; Miura K; Long CA; Zitzmann N; Draper SJ
    mSphere; 2021 Aug; 6(4):e0064721. PubMed ID: 34378982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.
    Lavie M; Dubuisson J; Belouzard S
    J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M
    Abosheasha MA; El-Gowily AH
    Drug Dev Res; 2021 Apr; 82(2):217-229. PubMed ID: 32984987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis.
    Rodal Canales FJ; Pérez-Campos Mayoral L; Hernández-Huerta MT; Sánchez Navarro LM; Matias-Cervantes CA; Martínez Cruz M; Cruz Parada E; Zenteno E; Ramos-Martínez EG; Pérez-Campos Mayoral E; Romero Díaz C; Pérez-Campos E
    Sci Rep; 2021 Nov; 11(1):22288. PubMed ID: 34782703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.